[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioDelivery Sciences International\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100341057",false,"NCT03720613","Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database","Inclusion Criteria:\n\n* At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date)\n* At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply\n* At least 18 years of age or older on the index date\n* At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date\n\nExclusion Criteria:\n\n* Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date\n* Any cancer treatment or cancer pain diagnosis within six months before or on the index date\n* Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date","ALL","18 Years",{"count":18,"type":19},34532,"ESTIMATED","OBSERVATIONAL","The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.",[23],"Opioid-induced Constipation",[25,26,27,28,29],"naloxegol","major adverse cardiovascular event (MACE)","opioid induced constipation (OIC)","lubiprostone","naldemedine","RECRUITING","2025-02-10",{"date":33,"type":34},"2025-02-12","ACTUAL",{"date":36,"type":34},"2019-01-04",{"date":38,"type":19},"2030-11-01",{"name":40,"class":41},"BioDelivery Sciences International","INDUSTRY",""]